Short answer
ARVINAS, INC. (ARVN) filed an 8-K current report with the SEC on May 1, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). FDA approval for VEPPANU™ (vepdegestrant) in ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
ARVINAS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA approval for VEPPANU™ (vepdegestrant) in ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer
- Eligible patients: adults with progression after at least one line of endocrine-based therapy
- Approval requires detection using an FDA-authorized test
- Commercial launch potential transforms vepdegestrant from development-stage asset into an approved oncology product
Item 8.01 · Other Events
- FDA approved VEPPANU for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy
- First FDA-approved PROTAC protein degrader, establishing Arvinas in a new therapeutic category
- $50.0 million development milestone payment due from Pfizer under the 2021 collaboration agreement
- Milestone proceeds offset amounts owed to Yale under the amended 2024 license agreement
- Commercialization partner selection remains pending, creating a near-term launch execution catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARVINAS, INC. 8-K filings
Get the next ARVN 8-K as it lands
Follow ARVN for push alerts, or ask the research agent what this filing means.